Lack of sleep may increase IFG risk, study finds
NEW YORK Lack of beauty sleep may up one’s risk of developing a condition that leads to diabetes and heart disease, a new study found.
Researchers from Warwick Medical School and the State University of New York at Buffalo examined six years of data from 1,455 participants in the Western New York Health Study, all of whom were between the ages of 35 and 79 years, and found that people who sleep less than six hours a night may be three times more likely to develop incident-impaired fasting glycaemia. IFG causes the body to be unable to regulate glucose as efficiently as it should.
Lead author at Warwick Medical School Dr. Saverio Stranges said: "We found that short sleep, less than six hours, was associated with a significant, threefold increased likelihood of developing IFG, compared [with] people who got an average of six to eight hours sleep a night. Previous studies have shown that short sleep duration results in a 28% increase in mean levels of the appetite stimulating hormone ghrelin so it can affect feeding behaviors. Other studies have also shown that a lack of sleep can decrease glucose tolerance and increases the production of cortisol, a hormone produced in response to stress."
Stranges added that, "more research is needed, but our study does suggest a very strong correlation between lack of sleep and Type 2 diabetes and heart disease."
The study was published in the journal Annals of Epidemiology.
AstraZeneca promotes healthy lifestyles with Crestor
WILMINGTON, Del. With September marked as National Cholesterol Education Month, drug maker AstraZeneca is using the occasion to push lifestyles that promote low cholesterol, the Anglo-Swedish company said.
AstraZeneca, which markets the cholesterol-lowering drug Crestor (rosuvastatin calcium), is pushing such habits as a healthy diet and exercise as ways to keep cholesterol down. According to the American Heart Association, 102 million Americans ages 20 years and older have borderline-high or high cholesterol.
“The patient-doctor partnership is one of the most critical relationships you can have, and National Cholesterol Education Month can be a reminder to see your doctor, talk about your cholesterol numbers and target goal, and understand how to assess your cardiovascular risk,” physician and founder of the Texas-based Legacy Heart Center Waenard Miller said in a statement on behalf of AstraZeneca.
LifeNexus introduces personal health card
BROOMFIELD, Colo. LifeNexus recently introduced its personal health card, a dual-purpose payment/loyalty card that comes equipped with an embedded microprocessor, the iChip, designed for an individually controlled health platform.
The personal health card can be used to maintain personal health records by securely transferring accurate information at the time and point of need. This will allow professionals access to a patient’s personal health record through card-based consumer authorization, which is both encrypted and password-protected.
The card is EMV-compliant and can be used at the retail pharmacy point of sale for medical/prescription data along with loyalty and/or payment features, LifeNexus noted.
The personal health record also can be directly linked to an unlimited number of disparate databases.
“This platform could offer a retailer a very unique healthcare platform, while enhancing loyalty and potentially prescription adherence,” the company stated. “Pharmacy is quickly becoming the front door to health care, and … an all-encompassing card program like the LifeNexus personal health card can help enhance the retailer’s efforts to be that ‘gateway’ to good health care.”